Number III -: Mucous membrane pemphigoid

被引:40
作者
Bagan, J
Lo Muzio, L
Scully, C [1 ]
机构
[1] UCL, Eastman Dent Inst, 256 Grays Inn Rd, London WC1X 8LD, England
[2] Univ Valencia, E-46003 Valencia, Spain
[3] Univ Foggia, Foggia, Italy
关键词
pemphigoid; skin; autoimmune; corticosteroids; immunosuppressants; oral;
D O I
10.1111/j.1601-0825.2005.01140.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Mucous membrane pemphigoid (MMP) is a sub-epithelial vesiculobullous disorder. It is now quite evident that a number of sub-epithelial vesiculobullous disorders may produce similar clinical pictures, and also that a range of variants of MMP exist, with antibodies directed against various hemidesmosomal components or components of the epithelial basement membrane. The term immune-mediated sub-epithelial blistering diseases (IMSEBD) has therefore been used. Immunological differences may account for the significant differences in their clinical presentation and responses to therapy, but unfortunately data on this are few. The diagnosis and management of IMSEBD on clinical grounds alone is impossible and a full history, general, and oral examination, and biopsy with immunostaining are now invariably required, sometimes supplemented with other investigations. No single treatment regimen reliably controls all these disorders, and it is not known if the specific subsets of MMP will respond to different drugs. Currently, apart from improving oral hygiene, immunomodulatory-especially immunosuppressive-therapy is typically used to control oral lesions. The present paper reviews pemphigoid, describing the present understanding of this fascinating clinical phenotype, summarising the increasing number of subsets with sometimes-different natural histories and immunological features, and outlining current clinical practice.
引用
收藏
页码:197 / 218
页数:22
相关论文
共 278 条
  • [1] CYCLOPHOSPHAMIDE (CYTOXAN) - A REVIEW ON RELEVANT PHARMACOLOGY AND CLINICAL USES
    AHMED, AR
    HOMBAL, SM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 11 (06) : 1115 - 1126
  • [2] AZATHIOPRINE
    AHMED, AR
    MOY, R
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 1981, 20 (07) : 461 - 467
  • [3] CICATRICIAL PEMPHIGOID
    AHMED, AR
    HOMBAL, SM
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 1986, 25 (02) : 90 - 96
  • [4] Ahmed AR, 2001, ARCH DERMATOL, V137, P1181
  • [5] CICATRICIAL PEMPHIGOID
    AHMED, AR
    KURGIS, BS
    ROGERS, RS
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (06) : 987 - 1001
  • [6] ASSOCIATION OF DQW7 (DQB1-STAR-0301) WITH OCULAR CICATRICIAL PEMPHIGOID
    AHMED, AR
    FOSTER, S
    ZALTAS, M
    NOTANI, G
    AWDEH, Z
    ALPER, CA
    YUNIS, EJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (24) : 11579 - 11582
  • [7] Aho S, 1999, J CELL BIOCHEM, V72, P356, DOI 10.1002/(SICI)1097-4644(19990301)72:3<356::AID-JCB5>3.0.CO
  • [8] 2-M
  • [9] A clinical study of oral mucous membrane pemphigoid
    Alkan, A
    Günhan, Ö
    Alkan, A
    Otan, F
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2003, 31 (04) : 340 - 344
  • [10] Anti-epiligrin (laminin 5) cicatricial pemphigoid
    Allbritton, JI
    Nousari, HC
    Anhalt, GJ
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1997, 137 (06) : 992 - 996